Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias
Pediatric Blood & Cancer, 08/21/2012
Elmoneim AA et al. – In pediatric patients with R/R leukemia, 20mg/m2/day is the maximum–tolerated dose (MTD) for clofarabine (CLO) in timed sequential combination with CY. Increased DNA damage with the use of this combination suggests a mechanism for the sequential timing of these two chemotherapeutic agents.